Safety & Efficacy of Imrecoxib Vs Celecoxib In Total Hip Arthroplasty: A Non-Inferiority Study .
Postoperative analgesic efficacy and safety of imrecoxib versus celecoxib in hip osteoarthritis patients undergoing total hip arthroplasty: a multi-center, randomized, controlled, non-inferiority study.
Inflammopharmacology . 2023 Aug;31(4):1813-1822.156 patients undergoing total hip arthroplasty (THA) for hip osteoarthritis were randomized to receive either celecoxib (n=78) or imrecoxib (n=78). Outcomes of interest included pain at rest and with movement on a Visual Analog Scale (VAS), opioid consumption, Harris Hip Scores (HHS), quality of life on the EuroQol 5 Dimensions (EQ-5D) questionnaire, and the incidence of adverse events, all measured until postoperative day 7. Non-inferiority was tested between the two groups. No significant differences in resting and movement VAS pain scores were apparent between the two groups at all time points. Similarly, there were no differences in opioid consumption, HHS, EQ-5D, and adverse events between the two groups at all time points.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
